Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis
Global and Regional Health Technology Assessment · 09.04.2026 · 13 (1) · 79-86
DOI: 10.33393/grhta.2026.3671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 09.04.2026. Verfasst von Gian Marco Raspolini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hygiene, Department of Health Science and Public Health, Università Cattolica del Sacro Cuore, Rome - Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The duration of pricing and reimbursement (P&R) negotiations is a key performance indicator formedicines agencies in universal health coverage systems. In early 2024, the Italian Medicines Agency (AIFA) underwent a major reform, including the merging of the previous Scientific-Technical Committee and Price andReimbursement Committee into a single Scientific and Economic Committee. This study evaluates the reform’simpact on time to P&R determinations for new medicines in Italy.
Methods
A time-to-event analysis was conducted on 139 new chemical entities authorized by the EuropeanCommission (EC) between February 2021 and December 2023. The primary outcome was the time from marketingauthorization (MA) to publication of AIFA’s P&R determination. Kaplan-Meier curves and Cox proportionalhazards models were used to compare reclassification hazards between pre- (before March 2024) and postreformgroups of medicinal products, based on a fixed separation date, adjusting for antineoplastic therapeuticarea and pharmaceutical company size. Four sensitivity analyses tested the robustness of the results.
Results
The multivariate Cox model, adjusting for antineoplastics, products from major corporations, and orphanmedicines, showed that the reform was associated with an 84% increase in reclassification hazards (HR = 1.84,95% CI 1.20-2.82, p = 0.005). Sensitivity analyses corroborated these findings, showing even greater improvementswhen focusing on national evaluation timeframes (HR = 11.57 and HR = 3.91).
Conclusion
The consolidation of separate committees into a unified structure, as a part of the 2024 AIFA reform,was accompanied by accelerated P&R negotiations for new medicines in Italy, demonstrating that structural optimization of health technology assessment processes may enhance system efficiency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Hygiene, Department of Health Science and Public Health, Università Cattolica del Sacro Cuore, Rome - Italy.
- These authors equally contributed to the work.
- Department of Human Sciences, Society and Health, University of Cassino and Southern Lazio, Cassino - Italy.
- European University of Technology EUt+, European Union, Cassino - Italy.
- Department of Life Sciences, Health and Health Professions, Link Campus University, Rome - Italy.
- Unit of Hospital Hygiene, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome - Italy.
ORCID-Profile: Gian Marco Raspolini, Bruno Federico, Mario Cesare Nurchis, Gianfranco Damiani, Pierluigi Navarra
Zitieren
APA
Raspolini, G. M., Federico, B., Nurchis, M. C., Damiani, G., Cocciolo, R., Turella, P., Pilunni, D., & Navarra, P. (2026). Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis. Global and Regional Health Technology Assessment, 13(1), 79-86. https://doi.org/10.33393/grhta.2026.3671
Vancouver
Raspolini GM, Federico B, Nurchis MC, Damiani G, Cocciolo R, Turella P, et al. Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis. Global and Regional Health Technology Assessment. 2026;13(1):79-86. doi:10.33393/grhta.2026.3671
BibTeX
@article{Raspolini2026,
author = {Raspolini, Gian Marco and Federico, Bruno and Nurchis, Mario Cesare and Damiani, Gianfranco and Cocciolo, Raffaella and Turella, Paola and Pilunni, Daniela and Navarra, Pierluigi},
title = {Italian Medicines Agency’s reform and time until pricing and reimbursement decisions: a time-to-event analysis},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {79--86},
doi = {10.33393/grhta.2026.3671}
}
EUVIMED